Prioritization of comparative effectiveness research topics in hospital pediatrics

Ron Keren1, Xianqun Luan, Russell Localio

  • 1Division of General Pediatrics, Center for Pediatric Clinical Effectiveness, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA. keren@email.chop.edu

Insights

Prioritizing pediatric research requires analyzing hospital costs and resource use. This study identifies high-cost, high-prevalence conditions with significant cost variation for effective research focus.

Area of Science:

  • Health Services Research
  • Pediatric Hospital Medicine
  • Health Economics

Background:

  • Comparative effectiveness research (CER) is crucial for optimizing pediatric healthcare.
  • Prioritizing CER topics requires understanding disease prevalence, cost, and resource utilization variation.
  • Administrative and billing data offer a valuable resource for such analyses.

Purpose of the Study:

  • To prioritize comparative effectiveness research topics in hospital pediatrics.
  • To utilize data on prevalence, cost, and resource utilization variation for prioritization.
  • To identify pediatric conditions that warrant further CER.

Main Methods:

  • Retrospective analysis of administrative and billing data from 38 US children's hospitals (2004-2009).
  • Included conditions accounting for 80% of all encounters or charges.
  • Measured condition-specific prevalence, total standardized cost, and interhospital cost variation using intraclass correlation coefficients and outlier hospital analysis.

Main Results:

  • The 10 most expensive conditions constituted 36% of total standardized costs among 495 conditions.
  • Of 77 high-prevalence/high-cost conditions, 26 showed significant interhospital cost variation (ICC > 0.10), with 5 exceeding ICC > 0.30.
  • Conditions like tonsillectomy, otitis media, and appendicitis surgery exhibited high cost, prevalence, and significant interhospital cost variation.

Conclusions:

  • Standardized hospital costs derived from administrative and billing data can effectively identify high-priority CER topics.
  • Conditions that are high-cost, high-prevalence, and demonstrate high resource utilization variation are prime candidates for CER.
  • This approach facilitates evidence-based resource allocation for pediatric research.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...